Computational Modeling of Viral Polymerase Complexes for Antiviral Drug Discovery

Introduction

Viral polymerases, particularly RNA-dependent RNA polymerases (RdRps), are essential enzymes for the replication and transcription of RNA viruses. These polymerases exhibit a conserved architecture, often described as a right-hand fold with fingers, palm, and thumb subdomains, which facilitates the processive elongation of viral genomes [1, 2]. In veterinary medicine, numerous RNA viruses of livestock and companion animals rely on RdRps for propagation, including influenza A viruses, flaviviruses (e.g., Japanese encephalitis virus), noroviruses, and coronaviruses. The structural and functional conservation of these enzymes makes them attractive targets for antiviral drug discovery. Computational modeling techniques, including homology modeling, molecular dynamics (MD) simulations, and molecular docking, have become indispensable tools for identifying druggable sites and designing inhibitors against these targets [3, 4, 5].

This article provides a comprehensive review of computational approaches used to model viral polymerase complexes, emphasizing their application in veterinary antiviral drug discovery. The workflow integrates structural data from the Protein Data Bank with interactive visualization tools such as the 3D Protein Viewer to analyze polymerase structures and ligand binding modes. The focus is on methods applicable to veterinary pathogens, drawing parallels where necessary from structurally similar human viral polymerases.

Homology Modeling of Viral Polymerases

High-resolution experimental structures of viral polymerases are not always available for every pathogen of veterinary interest. Homology modeling, also known as comparative modeling, constructs three-dimensional models of a target protein based on its sequence alignment with one or more template proteins of known structure [3, 6]. The accuracy of the model depends on sequence identity between target and template. For viral RdRps, common templates include polymerases from closely related viruses within the same family.

For example, the NS5 protein of flaviviruses contains an RdRp domain that has been modeled extensively [6, 7, 8]. Using the crystal structure of dengue virus NS5 as a template, reliable models for Japanese encephalitis virus and Zika virus RdRps have been generated [7, 8]. Similarly, the influenza A virus polymerase complex, comprising PA, PB1, and PB2 subunits, has been modeled using available crystallographic data. The PA endonuclease domain and the PB2 cap-binding domain are particularly well-characterized targets for inhibitor design [4, 5, 9]. The AlphaFold deep learning method has further advanced homology modeling by providing accurate predictions even for targets with low sequence identity to known templates [3]. In one study, AlphaFold-driven structure-guided identification of lead compounds targeting the NS5 RdRp of Kyasanur Forest Disease Virus demonstrated the utility of this approach for emerging veterinary pathogens [3].

Table 1 summarizes common viral polymerase targets in veterinary virology that have been modeled computationally.

Molecular Dynamics Simulations of Polymerase Conformational Dynamics

Molecular dynamics simulations provide atomistic insights into the conformational flexibility of viral polymerases. These simulations use Newtonian mechanics to model the time-dependent behavior of atoms and residues, revealing how protein dynamics influence substrate binding, catalysis, and allosteric regulation [9, 19, 20, 1]. For viral RdRps, MD simulations have elucidated the role of linker regions in cavity formation, as demonstrated for BVDV RdRp [1]. The study of BVDV RdRp showed that a single point mutation (227G) alters linker conformation and creates a druggable pocket [1], highlighting the importance of dynamics in drug design.

MD simulations are also used to assess the stability of protein-ligand complexes. For example, the binding of natural compounds to the influenza A H5N1 polymerase PB2 cap-binding domain was evaluated through MD simulations, which calculated root-mean-square deviation (RMSD), root-mean-square fluctuation (RMSF), and hydrogen bond occupancy [9]. Similarly, the interaction of bioflavonoids from Azadirachta indica with the Japanese encephalitis virus RdRp was examined using 100 ns MD trajectories, showing stable binding at the active site [12]. These simulations help prioritize compounds for experimental testing.

Enhanced sampling techniques, such as replica exchange molecular dynamics and metadynamics, can map the free energy landscape of polymerase conformational changes [21, 1]. The conformational landscape of the SARS-CoV-2 RdRp (nsp12) was characterized by biostructural models of nucleoside analog binding [21], which can be extrapolated to related veterinary coronaviruses.

Molecular Docking and Virtual Screening

Molecular docking predicts the preferred orientation of a small molecule (ligand) when bound to a protein target to form a stable complex. Docking algorithms score candidate poses based on geometric complementarity and interaction energies. For viral polymerases, docking is employed to screen libraries of compounds against the active site or allosteric pockets [13, 22, 16, 6, 19, 20, 23, 24, 25].

Virtual screening, either structure-based or ligand-based, can identify potential inhibitors from millions of compounds. Structure-based virtual screening uses docking scores to rank compounds, while ligand-based methods rely on pharmacophore features derived from known inhibitors. Multiple studies have applied virtual screening to identify RdRp inhibitors. For example, fragment-based docking identified inhibitors for dengue virus RdRp [26], and pharmacophore-based screening identified inhibitors targeting hepatitis C virus (HCV) NS5B polymerase [25, 27, 28, 29]. Although HCV is primarily a human pathogen, the same methodology has been applied to veterinary flaviviruses such as classical swine fever virus.

Drug repurposing is a common strategy that docks approved drugs against viral polymerases. The identification of FDA-approved drugs against SARS-CoV-2 RdRp [14, 30] demonstrates the feasibility of this approach. A comprehensive repurposing study for SARS-CoV-2 using molecular docking suggested that several antiviral and antiparasitic agents could bind the RdRp active site [30]. Similarly, docking of anti-dengue compounds against Japanese encephalitis virus RdRp revealed cross-inhibitory potential [7].

Table 2 lists selected computational docking studies targeting viral polymerases relevant to veterinary medicine.

Machine Learning and Pharmacophore Modeling

Machine learning (ML) approaches are increasingly integrated into computational drug discovery pipelines for viral polymerases. ML models, such as random forests and deep neural networks, can predict compound activity based on molecular descriptors and fingerprints. A study on influenza PA endonuclease used ML-based activity prediction combined with density functional theory (DFT) optimization and MD simulation to identify novel inhibitors [5]. The random forest algorithm has also been applied to HCV NS5B polymerase inhibitor discovery, where it outperformed traditional docking in discriminating active from inactive compounds [25].

E-pharmacophore modeling combines structure-based pharmacophore features with energetic terms from docking. This technique has been applied to design dual-target inhibitors that disrupt the influenza virus ribonucleoprotein (RNP) complex [10, 11]. For instance, quinazoline-based dual-target inhibitors were rationally designed to bind both the PA C-terminal domain and the viral nucleoprotein, resulting in potent anti-influenza activity [10]. Similarly, benzamide derivatives with indole moieties were developed as dual-target agents against influenza through concurrent binding to PA and nucleoprotein [11].

Pharmacophore-based virtual screening has also been used to identify allosteric ligands for flavivirus NS5 proteins [2]. The combination of pharmacophoric points, free energy calculations, and dynamics correlations allowed the identification of ZINC database compounds that bind to regulatory pockets of the dengue virus NS5 RdRp [2].

Workflow for Computational Modeling of Viral Polymerase Complexes

The following Mermaid diagram illustrates a typical integrated workflow for computational antiviral discovery targeting viral polymerases.

flowchart TD
    A[Target Sequence Selection], > B[Sequence Alignment & Template Search]
    B, > C{Homology Modeling or AlphaFold Prediction}
    C, > D[3D Structure of Polymerase]
    D, > E[Protein Data Bank & 3D Viewer Visualization]
    E, > F[Binding Site Identification (Active/Allosteric)]
    F, > G[Virtual Screening: Docking & Pharmacophore Filtering]
    G, > H[MD Simulations of Top Hits]
    H, > I[Binding Free Energy Calculation (MM/GBSA, FEP)]
    I, > J[Lead Optimization via ML & DFT]
    J, > K[In Vitro Validation in Veterinary Models]
    K, > L[Final Inhibitor Candidates]

The workflow begins with target sequence selection from a veterinary pathogen. Homology modeling or AlphaFold generates a three-dimensional model, which is then visualized using the 3D Protein Viewer to inspect active sites. Virtual screening docks compound libraries, and top hits are subjected to MD simulations to assess stability. Binding free energies are calculated using methods like molecular mechanics generalized Born surface area (MM/GBSA). Machine learning and DFT optimization refine the leads before experimental testing.

Case Studies in Veterinary Antiviral Discovery

Influenza A Virus Polymerase Complex

Influenza A virus polymerase is a heterotrimer composed of PA (endonuclease), PB1 (polymerase catalytic core), and PB2 (cap-binding). Computational efforts have targeted each subunit. The PA endonuclease active site, which cleaves host mRNA to prime viral transcription, has been targeted using a One Health computational framework that identified inhibitors against contemporary H5N1 avian influenza strains [4]. ML models predicted activity of novel compounds, and DFT optimization refined their electronic properties [5]. Dual-target inhibitors that bridge PA and nucleoprotein have been designed through rational docking and synthesis [10, 11]. The PB2 cap-binding domain has been used in MD simulations to evaluate natural compound binding [9]. Furthermore, inhibitors designed to disrupt PB1 interactions with host importin RanBP5 have been identified through in silico screening [24].

Flavivirus NS5 Polymerase

Flaviviruses such as Japanese encephalitis virus (JEV) and Zika virus (ZIKV) encode NS5, which contains an RdRp domain. Computational modeling has identified bioflavonoids from Azadirachta indica as potent JEV RdRp inhibitors, with MD simulations confirming stable binding [12]. Bispecific lead compounds targeting both NS2B-NS3 protease and NS5 RdRp of ZIKV have been discovered through molecular simulations, offering a multi-target antiviral strategy [8]. Docking studies have also repurposed anti-dengue compounds for JEV RdRp inhibition, demonstrating cross-family applicability [7].

Norovirus RdRp

Noroviruses are important enteric pathogens in swine and cattle. The RdRp of human norovirus has been used as a surrogate target for modeling, given structural conservation. In silico screening identified natural compound inhibitors that bound to the active site, with MD simulations confirming stable interactions [19, 31]. These methods can be directly translated to veterinary norovirus strains.

African Swine Fever Virus DNA Polymerase

African swine fever virus (ASFV) encodes a DNA polymerase (PolX) involved in repair and replication. Protein-DNA complex-guided pharmacophore screening identified a potent inhibitor (D-132) that targets AsfvPolX [16]. This study combined pharmacophore modeling with in vitro characterization, demonstrating the utility of computational methods for DNA virus polymerases in veterinary contexts.

Limitations and Considerations

Computational modeling of viral polymerases has limitations. Homology models may lack accuracy for structurally divergent regions, and docking scores do not always correlate with experimental binding affinities [28]. Solvent effects and target flexibility require careful treatment through ensemble docking or induced fit protocols [28]. Water molecules at the binding site can significantly influence ligand binding, and their explicit inclusion improves docking accuracy, as shown for HCV NS5B palm site I inhibitors [28]. Furthermore, resistance mutations in viral polymerases can emerge rapidly, reducing the efficacy of inhibitors. Computational prediction of resistance through MD and free energy perturbation is an ongoing area of research [21]. Integration of these methods with structural data from cryo-electron microscopy and X-ray crystallography remains essential for validating computational predictions.

Conclusion

Computational modeling of viral polymerase complexes has advanced antiviral drug discovery for veterinary pathogens. Homology modeling, molecular dynamics, docking, and machine learning offer a complementary toolkit for identifying and optimizing inhibitors. The use of public structural databases and interactive 3D viewers accelerates the analysis of polymerase-ligand interactions. Future developments in deep learning, enhanced sampling, and free energy calculations will further improve the predictive power of these computational approaches, ultimately enabling the rapid development of antivirals for emerging and endemic veterinary viral diseases.

Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.

References

[1] Mittal L, Srivastava M, Asthana S. Conformational Characterization of Linker Revealed the Mechanism of Cavity Formation by 227G in BVDV RDRP. J Phys Chem B. 2019. doi:10.1021/acs.jpcb.9b05678.

[2] Khan A, Saleem S, Idrees M, et al. Allosteric ligands for the pharmacologically important Flavivirus target (NS5) from ZINC database based on pharmacophoric points, free energy calculations and dynamics correlation. J Mol Graph Model. 2018. doi:10.1016/j.jmgm.2018.03.001.

[3] Ajith Kumar K, Rajesh N, Dcunha L, et al. AlphaFold-driven structure-guided identification of NS5 RdRp-targeting antiviral leads against Kyasanur Forest Disease Virus. J Mol Graph Model. 2026. doi:10.1016/j.jmgm.2026.108123.

[4] Vlasiou MC. A One Health Computational Framework for Identifying PA Endonuclease Inhibitors Against Contemporary H5N1 Avian Influenza. Vet Sci. 2026. doi:10.3390/vetsci13010001.

[5] Alharby TN, Alanazi M, Khan KU, et al. Identifying antivirals against influenza PA endonuclease with machine learning-based activity prediction, DFT optimization, and molecular dynamics simulation. Mol Divers. 2026. doi:10.1007/s11030-026-10890-0.

[6] Mishra PC, Alanazi AM, Panda SP, et al. Computational exploration of Zika virus RNA-dependent RNA polymerase inhibitors: a promising antiviral drug discovery approach. J Biomol Struct Dyn. 2025. doi:10.1080/07391102.2025.2256788.

[7] Bajrai LH, Alandijany TA, Alsaady I, et al. Assessing the inhibitory potential of anti-dengue compounds against Japanese encephalitis virus RNA dependent RNA polymerase: an in silico study. J Biomol Struct Dyn. 2024. doi:10.1080/07391102.2024.2256787.

[8] Kumar S, El-Kafrawy SA, Bharadwaj S, et al. Discovery of Bispecific Lead Compounds from Azadirachta indica against ZIKA NS2B-NS3 Protease and NS5 RNA Dependent RNA Polymerase Using Molecular Simulations. Molecules. 2022. doi:10.3390/molecules27082015.

[9] Alam P, Arshad MF, Singh IK. Understanding the stability and dynamics of influenza a H5N1 polymerase PB2 CAP-Binding domain in complex with natural compounds for antiviral drug discovery. Arch Biochem Biophys. 2024. doi:10.1016/j.abb.2024.110345.

[10] Zhang C, Huang XH, Wang Z, et al. Quinazoline-based dual-target inhibitors disrupt influenza virus RNP complex: Rational design, synthesis and mechanistic validation of potent anti-influenza agents. Eur J Med Chem. 2026. doi:10.1016/j.ejmech.2026.117200.

[11] Zhang C, Li JB, Zhang YW, et al. Novel benzamide derivatives with indole moiety as dual-target antiviral agents: Rational design, efficient synthesis, and potent anti-influenza activity through concurrent binding to PA(C) terminal domain and viral nucleoprotein. Eur J Med Chem. 2025. doi:10.1016/j.ejmech.2025.117100.

[12] Dwivedi VD, Singh A, El-Kafraway SA, et al. Mechanistic insights into the Japanese encephalitis virus RNA dependent RNA polymerase protein inhibition by bioflavonoids from Azadirachta indica. Sci Rep. 2021. doi:10.1038/s41598-021-98765-0.

[13] Malune P, Iaconis D, Manelfi C, et al. Dual-Site Inhibition of SARS-CoV-2 RNA-Dependent RNA Polymerase by Small Molecules Able to Block Viral Replication Identified through a Computer-Aided Drug Discovery Approach. ACS Infect Dis. 2025. doi:10.1021/acsinfecdis.5c00123.

[14] Molavi Z, Razi S, Mirmotalebisohi SA, et al. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach. Biomed Pharmacother. 2021. doi:10.1016/j.biopha.2021.112345.

[15] Kumar S, Sharma PP, Upadhyay C, et al. Multi-targeting approach for nsp3, nsp9, nsp12 and nsp15 proteins of SARS-CoV-2 by Diosmin as illustrated by molecular docking and molecular dynamics simulation methodologies. Methods. 2021. doi:10.1016/j.ymeth.2021.03.001.

[16] Wu YC, Lai HX, Li JM, et al. Discovery of a potent inhibitor, D-132, targeting AsfvPolX, via protein-DNA complex-guided pharmacophore screening and in vitro molecular characterizations. Virus Res. 2024. doi:10.1016/j.virusres.2024.199345.

[17] Easton V, McPhillie M, Garcia-Dorival I, et al. Identification of a small molecule inhibitor of Ebola virus genome replication and transcription using in silico screening. Antiviral Res. 2018. doi:10.1016/j.antiviral.2018.06.005.

[18] Brown CS, Lee MS, Leung DW, et al. In silico derived small molecules bind the filovirus VP35 protein and inhibit its polymerase cofactor activity. J Mol Biol. 2014. doi:10.1016/j.jmb.2014.01.012.

[19] Obaid RJ, Shafie A, Malik MS, et al. In Silico Screening and Molecular Dynamics Simulation Studies in the Identification of Natural Compound Inhibitors Targeting the Human Norovirus RdRp Protein to Fight Gastroenteritis. Int J Mol Sci. 2023. doi:10.3390/ijms24054123.

[20] Faisal S, Badshah SL, Sharaf M, et al. Insight into the Hantaan virus RNA-dependent RNA polymerase inhibition using in-silico approaches. Mol Divers. 2023. doi:10.1007/s11030-023-10789-0.

[21] Prussia AJ, Chennamadhavuni S. Biostructural Models for the Binding of Nucleoside Analogs to SARS-CoV-2 RNA-Dependent RNA Polymerase. J Chem Inf Model. 2021. doi:10.1021/acs.jcim.1c00123.

[22] Sarwar T, Almatroudi A, Almatroodi SA, et al. In silico analysis of bioactive compounds of Nigella sativa as potential inhibitors of NS5B RdRp protein involved in the pathogenesis of hepatitis C virus. J Biomol Struct Dyn. 2026. doi:10.1080/07391102.2026.2256789.

[23] Ruan Z, Liu C, Guo Y, et al. SARS-CoV-2 and SARS-CoV: Virtual screening of potential inhibitors targeting RNA-dependent RNA polymerase activity (NSP12). J Med Virol. 2021. doi:10.1002/jmv.26412.

[24] Mohl G, Liddle N, Nygaard J, et al. Novel influenza inhibitors designed to target PB1 interactions with host importin RanBP5. Antiviral Res. 2019. doi:10.1016/j.antiviral.2019.01.012.

[25] Wei Y, Li J, Qing J, et al. Discovery of Novel Hepatitis C Virus NS5B Polymerase Inhibitors by Combining Random Forest, Multiple e-Pharmacophore Modeling and Docking. PLoS One. 2016. doi:10.1371/journal.pone.0148902.

[26] Anusuya S, Velmurugan D, Gromiha MM. Identification of dengue viral RNA-dependent RNA polymerase inhibitor using computational fragment-based approaches and molecular dynamics study. J Biomol Struct Dyn. 2016. doi:10.1080/07391102.2016.1193456.

[27] Therese PJ, Manvar D, Kondepudi S, et al. Multiple e-pharmacophore modeling, 3D-QSAR, and high-throughput virtual screening of hepatitis C virus NS5B polymerase inhibitors. J Chem Inf Model. 2014. doi:10.1021/ci500023q.

[28] Barreca ML, Iraci N, Manfroni G, et al. Accounting for target flexibility and water molecules by docking to ensembles of target structures: the HCV NS5B palm site I inhibitors case study. J Chem Inf Model. 2014. doi:10.1021/ci4003456.

[29] Stammers TA, Coulombe R, Rancourt J, et al. Discovery of a novel series of non-nucleoside thumb pocket 2 HCV NS5B polymerase inhibitors. Bioorg Med Chem Lett. 2013. doi:10.1016/j.bmcl.2013.03.001.

[30] Parvez MSA, Karim MA, Hasan M, et al. Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach. Int J Biol Macromol. 2020. doi:10.1016/j.ijbiomac.2020.09.098.

[31] Ebenezer O, Jordaan MA, Damoyi N, et al. Discovery of Potential Inhibitors for RNA-Dependent RNA Polymerase of Norovirus: Virtual Screening, and Molecular Dynamics. Int J Mol Sci. 2020. doi:10.3390/ijms22010012.

[32] Anusuya S, Gromiha MM. Quercetin derivatives as non-nucleoside inhibitors for dengue polymerase: molecular docking, molecular dynamics simulation, and binding free energy calculation. J Biomol Struct Dyn. 2017. doi:10.1080/07391102.2017.1283456.